Luciferase Reporter Cell Line - SNU-387

SNU-387 cells are a human hepatocellular carcinoma (HCC)-derived cell line widely used as an in vitro model for studying liver cancer biology and hepatocellular tumor progression. These cells originate from a poorly differentiated hepatic carcinoma and are characterized by epithelial-like morphology, high proliferative activity, and genetic alterations commonly associated with advanced HCC. SNU-387 cells exhibit dysregulated signaling pathways involved in cell growth, apoptosis resistance, and metabolic reprogramming, making them suitable for investigating molecular mechanisms underlying liver tumor development and therapeutic resistance. The Luciferase Reporter Cell Line – SNU-387 is generated by stable integration of a luciferase reporter gene under the control of pathway-responsive elements or specific transcriptional promoters within the parental SNU-387 background, enabling real-time and quantitative monitoring of transcriptional and signaling activity while preserving the intrinsic characteristics of the original cancer cell line.

The Luciferase Reporter Cell Line – SNU-387 is widely applied in liver cancer research, drug screening, and signal transduction studies. It is particularly useful for evaluating key oncogenic and stress-related pathways in hepatocellular carcinoma, including Wnt/β-catenin, PI3K/AKT/mTOR, MAPK/ERK, and NF-κB signaling cascades. The luciferase-based readout provides a sensitive and robust method for quantifying pathway modulation in response to small molecules, biologics, or genetic interventions. This model is frequently used in high-throughput screening of anti-cancer and anti-fibrotic compounds, as well as in mechanistic studies of tumor growth, apoptosis, and metastasis. In addition, it supports compound efficacy evaluation and mechanism-of-action studies, offering a reliable and reproducible platform for both basic research and preclinical drug development in hepatocellular carcinoma.